Guggenheim has initiated coverage of Metsera (NASDAQ:MTSR) with a buy rating, citing the company's obesity drug candidates.

Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...

The performance artist Marina Abramovic celebrated the announcement of a new cultural center in a private home designed by ...

The trial of three men accused in the theft or sale of an 18-carat gold toilet that was a pricey piece of satirical art is ...

Wingstop (NASDAQ:WING – Get Free Report) was upgraded by analysts at Guggenheim from a “neutral” rating to a “buy” rating in ...

As previously reported, Guggenheim analyst Michael Schmidt initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $12 price ...

Guggenheim restated their buy rating on shares of Guardant Health (NASDAQ:GH – Free Report) in a report released on Monday ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

Be the first to know about the biggest and best luxury home sales and listings by signing up for our Mansion Deals email ...

The artist is known for creating futuristic, interactive environments that reflect on contemporary geopolitical and ...

LG and the Guggenheim New York proudly announce Ayoung Kim as the 2025 LG Guggenheim Award recipient. Kim is the third artist to be recognized as part of the LG Guggenheim Art and Technology ...

In Miami Beach, Fla., a waterfront estate asking $88 million has elements inspired by Manhattan’s Guggenheim Museum.